[1] 汪凯,董强,郁金泰,等.卒中后认知障碍管理专家共识2021[J].中国卒中杂志,2021,16(4):376-389.
[2] 王陇德,彭斌,张鸿祺,等.《中国脑卒中防治报告2020》概要[J].中国脑血管病杂志,2022,19(2):136-144.
[3] MIJAJLOVIĆ M D, PAVLOVIĆ A, BRAININ M,et al. Post-stroke dementia - a comprehensive review[J]. BMC Med, 2017,15(1):11.
[4] LUO J, YANG H, SONG B L. Mechanisms and regulation of cholesterol homeostasis[J]. Nat Rev Mol Cell Biol,2020,21(4):225-245.
[5] GOEDEKE L, FERNÁNDEZ-HERNANDO C. Regulation of cholesterol homeostasis[J]. Cell Mol Life Sci,2012, 69(6):915-930.
[6] KUMRAL E, GÜLLÜOĞLU H, ALAKBAROVA N, et al. Cognitive decline in patients with leukoaraiosis within 5 years after initial stroke[J]. J Stroke Cerebrovasc Dis, 2015, 24(10):2338-2347.
[7] CANTUTI-CASTELVETRI L, FITZNER D, BOSCH-QUERALT M, et al. Defective cholesterol clearance limits remyelination in the aged central nervous system[J]. Science, 2018,359(6376):684-688.
[8] KAPLAN P, TATARKOVA Z, SIVONOVA M K, et al. Homocysteine and mitochondria in cardiovascular and cerebrovascular systems[J]. Int J Mol Sci, 2020, 21(20):7698.
[9] ZHOU S, CHEN J, CHENG L,et al. Age-dependent association between elevated homocysteine and cognitive impairment in a post-stroke population: a prospective study[J]. Front Nutr, 2021, 8:691837.
[10] YAN H, YAN Z, NIU X, et al. Dl-3-n-butylphthalide can improve the cognitive function of patients with acute ischemic stroke: a prospective intervention study[J]. Neurol Res, 2017, 39(4):337-343.
[11] ISLAM M R, KAURANI L, BERULAVA T, et al. A microRNA signature that correlates with cognition and is a target against cognitive decline[J]. EMBO Mol Med, 2021,13(11):e13659.
[12] WANG Z Q, LI K, HUANG J, et al. MicroRNA Let-7i is a promising serum biomarker for post-stroke cognitive impairment and alleviated OGD-induced cell damage in vitro by regulating Bcl-2[J]. Front Neurosci,2020,14:215.
[13] HUANG S, ZHAO J, HUANG D,et al. Serum miR-132 is a risk marker of post-stroke cognitive impairment[J]. Neurosci Lett, 2016, 615:102-106.
[14] SCHELLER J, CHALARIS A, SCHMIDT-ARRAS D,et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6[J]. Biochim Biophys Acta, 2011,1813(5):878-888.
[15] SCHULTZBERG M,LINDBERG C,ARONSSON A F,et al. Inflammation in the nervous system--physiological and pathophysiological aspects[J]. Physiol Behav, 2007,92(1/2):121-128.
[16] KIM H, SEO J S, LEE S Y, et al. AIM2 inflammasome contributes to brain injury and chronic post-stroke cognitive impairment in mice[J]. Brain Behav Immun, 2020,87:765-776.
[17] KULESH A, DROBAKHA V, KUKLINA E, et al. Cytokine response, tract-specific fractional anisotropy, and brain morphometry in post-stroke cognitive impairment[J]. J Stroke Cerebrovasc Dis, 2018, 27(7):1752-1759.
[18] BUNEVICIUS A, KAZLAUSKAS H, RASKAUSKIENE N, et al. Role of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and inteleukin-6 in predicting a poor outcome after a stroke[J]. Neuroimmunomodulation, 2015, 22(6):365-372.
[19] NARASIMHALU K, LEE J, LEONG Y L, et al. Inflammatory markers and their association with post stroke cognitive decline[J]. Int J Stroke,2015,10(4):513-518.
[20] BLACK S, KUSHNER I, SAMOLS D. C-reactive protein[J]. J Biol Chem, 2004, 279(47):48487-48490.
[21] BULZACKA E, BOYER L, SCHüRHOFF F, et al. Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the Multicentric FACE-SZ Dataset[J]. Schizophr Bull, 2016,42(5):1290-1302.
[22] IRIMIE C A, VA＾RCIU M, IRIMIE M, et al. C-reactive protein and T3: new prognostic factors in acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2018,27(10):2731-2737.
[23] TEGELER C, O'SULLIVAN J L, BUCHOLTZ N, et al. The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive function-data from the Berlin Aging Study II[J]. Neurobiol Aging, 2016, 38:112-117.
[24] BETTCHER B M, WILHEIM R, RIGBY T, et al. C-reactive protein is related to memory and medial temporal brain volume in older adults[J]. Brain Behav Immun, 2012,26(1):103-108.
[25] STONE T W, DARLINGTON L G. Endogenous kynurenines as targets for drug discovery and development[J]. Nat Rev Drug Discov, 2002, 1(8):609-620.
[26] GUILLEMIN G J, KERR S J, SMYTHE G A, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection[J]. J Neurochem, 2001,78(4):842-853.
[27] COGO A, MANGIN G, MAI¨ER B, et al. Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline[J]. Mol Neurodegener, 2021, 16(1):7.
[28] LAURANS L, VENTECLEF N, HADDAD Y, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health[J]. Nat Med, 2018, 24(8):1113-1120.
[29] GOLD A B, HERRMANN N, SWARDFAGER W, et al. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment[J]. J Neuroinflammation, 2011, 8:17.
[30] GRAILLE M, WILD P, SAUVAIN J J, et al. Urinary 8-OHdG as a biomarker for oxidative stress: a systematic literature review and meta-analysis[J]. Int J Mol Sci, 2020,21(11):3743.
[31] LIU Z, LIU Y, TU X, et al. High serum levels of malondialdehyde and 8-OHdG are both associated with early cognitive impairment in patients with acute ischaemic stroke[J]. Sci Rep, 2017, 7(1):9493.
[32] SU D, LI P, WANG X, et al. Observing malondialdehyde-mediated signaling pathway in cerebral ischemia reperfusion injury with a specific Nanolight[J]. Anal Chem, 2020,92(3):2748-2755.
[33] SIMANI L, RYAN F, HASHEMIFARD S, et al. Serum coenzyme Q10 is associated with clinical neurological outcomes in acute stroke patients[J]. J Mol Neurosci, 2018, 66(1):53-58.
[34] WANG X, PENG Y, ZHOU H, et al. The effects of enriched rehabilitation on cognitive function and serum glutamate levels post-stroke[J]. Front Neurol, 2022,13:829090.
[35] ROSA A C, BRUNI N, MEINERI G, et al. Strategies to expand the therapeutic potential of superoxide dismutase by exploiting delivery approaches[J]. Int J Biol Macromol, 2021,168:846-865.
[36] BALENDRA V, SINGH S K. Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease[J]. Open Biol, 2021,11(6):210013.
[37] ZHANG M S, LIANG J H, YANG M J, et al. Low serum superoxide dismutase is associated with a high risk of cognitive impairment after mild acute ischemic stroke[J]. Front Aging Neurosci, 2022,14:834114. |
